BioSpace News Archive

G1 Therapeutics, Inc. announced the presentation of four posters that provide new-real world evidence indicating that trilaciclib administered prior to platinum-based chemotherapy in patients with extensive-stage small cell lung cancer lowers the rate of hospitalization and cytopenia events and may improve survival.

Microbix Biosystems Inc. announces that its quality assessment products are supporting a testing program for Human Papilloma Virus using molecular diagnostic technology at Dublin’s The Coombe Hospital, in the Republic of Ireland, an EU member-state.

Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023, at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2023.

Kymera Therapeutics, Inc. today announced that the first patient has been dosed in the randomized Phase 2 clinical trial in hidradenitis suppurativa (HS) evaluating KT-474.

Medicenna Therapeutics Corp. announced that the Company received a Staff Delisting Determination from the Listing Qualifications Department of the Nasdaq Stock Market, LLC, which notified the Company of the delisting of its securities from the Nasdaq Capital Market as a result of the Company’s failure to comply with the US$1.00 per share minimum bid price requirement.

Global biotechnology leader CSL and uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that the companies have received the 2023 Prix Galien USA Award in the category of Best Product for Rare/Orphan Diseases for HEMGENIX®.

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) (“PharmaDrug” or the “Company”), is pleased to announce that it has entered into a definitive agreement (the “Acquisition Agreement”) dated October 27, 2023 pursuant to which PharmaDrug will acquire all of the issued and outstanding shares of privately-held Securedose Synthetics Inc.

Innate Pharma SA announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below.

Orexo AB, announces that Robin Evers, Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S has become a member of the company´s Board of Directors.

Sanofi provided a comprehensive update regarding its Play to Win strategy.